Market Overview:
The Global Systemic Mastocytosis Treatment Market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of mastocytosis, rising awareness about systemic mastocytosis treatment, and technological advancements in systemic mastocytosis treatment. However, the high cost of systemic mastocytosis treatment may restrain the market growth. Based on type, the global systematic mastocytosis treatment market is segmented into AK-002, BLU-285, Brentuximab Vedotin, Crenolanib Besylate Cromolyn Sodium and others. Based on application, the global systematic mastocytosa treatment market is segmented into clinic hospital and homecare.
Product Definition:
Systemic mastocytosis treatment is the process of managing and treating the symptoms of systemic mastocytosis. This type of mastocytosis is a rare blood disorder in which too many mast cells are found in the body. These cells can cause problems such as skin rash, itching, diarrhea, stomach pain, shortness of breath, and an increased risk for leukemia. Treatment for systemic mastocytosis may include medications to help control symptoms, antibiotics if there is a bacterial infection, and sometimes surgery.
AK-002:
AK-002 is a novel oral drug developed by Akari Therapeutics for the treatment of Systemic Mastocytosis (SM). AK-002 is currently under phase II clinical trial and has shown positive results in Phase I study. The expected commercial launch of AK-002 is in 2019.
Mast cell refers to cells that are found in connective tissues such as bone, skin,.
BLU-285:
Blu-285 is a nucleoside analog used in the treatment of systemic mastocytosis. It is also known as GSK2895806 and Nucleoside Inhibitor II (NII). The drug has been studied to treat patients with mast cell cancer, multiple myeloma, and cutaneous systemic sclerosis. There are no current FDA-approved drugs for the treatment of Systemic Mastocytosis (SM) in Europe or Japan.
Application Insights:
The systemic mastocytosis clinic based treatment segment dominated the global market in 2017. This is due to the increasing prevalence of the disease and availability of advanced therapies. According to a study published by NCBI, in 2019, around 1 out of every 10 systemic mastocytosis patients are diagnosed at an early stage and receive treatment at clinics or hospitals. Thus, high unmet medical needs for SMMT cure coupled with availability of advanced therapies at affordable prices is expected to drive demand for SCT globally over the forecast period.
Hospital based MastCellular Sarcoma (MCS) treatments accounted for a significant share in 2018 owing to rising awareness about diagnosis & management options along with advancements made in drug development pipeline over recent years.
Regional Analysis:
North America dominated the global MSBT market in 2017. This can be attributed to the presence of key players, high treatment cost and availability of insurance coverage for systemic mastocytosis treatment. The U.S., which accounted for a major share in North America, is expected to witness significant growth over the forecast period owing to increasing R&D investments by pharmaceutical companies and rising healthcare expenditure by government agencies.
Asia Pacific is anticipated to register fastest CAGR during the forecast period due to unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging economies such as China & India & Japan (CIJ). Furthermore, growing awareness about various available treatments along with supportive government initiatives are expected drive regional growth over next eight years.
Growth Factors:
- Increasing incidence of systemic mastocytosis
- Growing awareness about systemic mastocytosis and its treatment options
- Rising demand for better and more effective systemic mastocytosis treatments
- Technological advancements in the field of systemic mastocytosis treatment 5. Availability of government funding for research on systemic mastocytosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Mastocytosis Treatment Market Research Report
By Type
AK-002, BLU-285, Brentuximab Vedotin, Crenolanib Besylate, Cromolyn Sodium, Others
By Application
Clinic, Hospital, Homecare
By Companies
AB Science SA, AbbVie Inc, Arog Pharmaceuticals Inc, Blueprint Medicines Corp, Bristol-Myers Squibb Company, Deciphera Pharmaceuticals LLC, Novartis AG, Patara Pharma Inc, Seattle Genetics Inc, Stemline Therapeutics Inc, AB Science SA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
193
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Systemic Mastocytosis Treatment Market Report Segments:
The global Systemic Mastocytosis Treatment market is segmented on the basis of:
Types
AK-002, BLU-285, Brentuximab Vedotin, Crenolanib Besylate, Cromolyn Sodium, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Homecare
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AB Science SA
- AbbVie Inc
- Arog Pharmaceuticals Inc
- Blueprint Medicines Corp
- Bristol-Myers Squibb Company
- Deciphera Pharmaceuticals LLC
- Novartis AG
- Patara Pharma Inc
- Seattle Genetics Inc
- Stemline Therapeutics Inc
- AB Science SA
Highlights of The Systemic Mastocytosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AK-002
- BLU-285
- Brentuximab Vedotin
- Crenolanib Besylate
- Cromolyn Sodium
- Others
- By Application:
- Clinic
- Hospital
- Homecare
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Mastocytosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic mastocytosis (SM) is a rare, life-threatening condition in which the body produces too many mast cells. These cells are responsible for releasing histamine and other chemicals that can cause inflammation and pain. Systemic mastocytosis treatment typically includes medications to control the symptoms and treatments for the underlying cause of SM, such as cancer or a genetic disorder.
Some of the major companies in the systemic mastocytosis treatment market are AB Science SA, AbbVie Inc, Arog Pharmaceuticals Inc, Blueprint Medicines Corp, Bristol-Myers Squibb Company, Deciphera Pharmaceuticals LLC, Novartis AG, Patara Pharma Inc, Seattle Genetics Inc, Stemline Therapeutics Inc, AB Science SA.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Systemic Mastocytosis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Systemic Mastocytosis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Systemic Mastocytosis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Systemic Mastocytosis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Systemic Mastocytosis Treatment Market Size & Forecast, 2020-2028
4.5.1 Systemic Mastocytosis Treatment Market Size and Y-o-Y Growth
4.5.2 Systemic Mastocytosis Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 AK-002
5.2.2 BLU-285
5.2.3 Brentuximab Vedotin
5.2.4 Crenolanib Besylate
5.2.5 Cromolyn Sodium
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Homecare
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Systemic Mastocytosis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Systemic Mastocytosis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 AK-002
9.6.2 BLU-285
9.6.3 Brentuximab Vedotin
9.6.4 Crenolanib Besylate
9.6.5 Cromolyn Sodium
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Homecare
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 AK-002
10.6.2 BLU-285
10.6.3 Brentuximab Vedotin
10.6.4 Crenolanib Besylate
10.6.5 Cromolyn Sodium
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Homecare
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 AK-002
11.6.2 BLU-285
11.6.3 Brentuximab Vedotin
11.6.4 Crenolanib Besylate
11.6.5 Cromolyn Sodium
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Homecare
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 AK-002
12.6.2 BLU-285
12.6.3 Brentuximab Vedotin
12.6.4 Crenolanib Besylate
12.6.5 Cromolyn Sodium
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Homecare
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 AK-002
13.6.2 BLU-285
13.6.3 Brentuximab Vedotin
13.6.4 Crenolanib Besylate
13.6.5 Cromolyn Sodium
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Homecare
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Systemic Mastocytosis Treatment Market: Competitive Dashboard
14.2 Global Systemic Mastocytosis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AB Science SA
14.3.2 AbbVie Inc
14.3.3 Arog Pharmaceuticals Inc
14.3.4 Blueprint Medicines Corp
14.3.5 Bristol-Myers Squibb Company
14.3.6 Deciphera Pharmaceuticals LLC
14.3.7 Novartis AG
14.3.8 Patara Pharma Inc
14.3.9 Seattle Genetics Inc
14.3.10 Stemline Therapeutics Inc
14.3.11 AB Science SA
